SCHEMBL17986906

SCHEMBL17986906

CC(C)(C)[Si](C)(C)OCc1cccnc1C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.53
MAPT P10636 2/20 0.53
CYP1A2 P05177 1/20 0.53
BACE1 P56817 1/20 0.44
ALDH1A1 P00352 5/20 0.42
ALOX15 P16050 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
CYP3A4 P08684 1/20 0.42
TSHR P16473 1/20 0.42
BLM P54132 1/20 0.42
AGER Q15109 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MYC P01106 1/20 0.39
GAA P10253 2/20 0.37
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM5 P08912 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29770728 1.00 KDM4E (0.53) KDM4EMAPTCYP1A2BACE1ALDH1A1
SCHEMBL15065360 0.89 BACE1 (0.44) KDM4EMAPTCYP1A2BACE1ALDH1A1
SCHEMBL7499938 0.85 BACE1 (0.41) KDM4EMAPTCYP1A2BACE1ALDH1A1
SCHEMBL29770723 0.83 L3MBTL1 (0.47) KDM4EMAPTBACE1ALDH1A1L3MBTL1
SCHEMBL17986908 0.83 L3MBTL1 (0.47) KDM4EMAPTBACE1ALDH1A1L3MBTL1
SCHEMBL3443405 0.83 BACE1 (0.42) KDM4EMAPTCYP1A2BACE1ALDH1A1
SCHEMBL16103379 0.80 BACE1 (0.43) KDM4EMAPTCYP1A2BACE1
SCHEMBL15068283 0.80 BACE1 (0.43) KDM4EMAPTCYP1A2BACE1ALDH1A1
SCHEMBL15068284 0.80 BACE1 (0.43) KDM4EMAPTCYP1A2BACE1ALDH1A1
SCHEMBL26906977 0.80 GPR132 (0.42) BACE1ALDH1A1NPSR1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125391-A1 PYRIMIDINE INDOLES AS CDK4 INHIBITORS INCYTE CORP (US) 2026-05-07 US disclosed
US-20240174662-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES CILAG AG (CH) 2024-05-30 US disclosed
EP-4284802-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES Janssen Biotech, Inc. (US) 2023-12-06 EP disclosed
WO-2022165530-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES JANSSEN BIOTECH, INC. (US) 2022-08-04 WO disclosed
WO-2016119707-A1 NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS HUTCHISON MEDIPHARMA LIMITED (CN) 2016-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125391-A1 PYRIMIDINE INDOLES AS CDK4 INHIBITORS CDK4, CCNA1, CCNO KDM4E 1827/4885MAPT 4474/4885CYP1A2 1622/4885
US-20240174662-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES SIK2, SIK1, SGK2 KDM4E 3286/4885MAPT 734/4885CYP1A2 4384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.